Unknown EARLY_PHASE1 INTERVENTIONAL 4-arm NCT05263817

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Sponsor: Yake Biotechnology Ltd.

Conditions Amyloidosis Autoimmune Hemolytic Anemia POEMS Syndrome Vasculitis

Interventions CD19/BCMA CAR T-cells

Updated 4 times since 2022 Last updated: Feb 21, 2022 Started: Oct 8, 2021 Primary completion: Oct 1, 2024 Completion: Oct 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05263817, this EARLY_PHASE1 trial focuses on Amyloidosis and Autoimmune Hemolytic Anemia and remains ongoing. Sponsored by Yake Biotechnology Ltd., it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Unknown EARLY_PHASE1

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Apr 2022 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yake Biotechnology Ltd.
Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China